A detailed history of Broderick Brian C transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Broderick Brian C holds 11,817 shares of BMY stock, worth $637,645. This represents 0.11% of its overall portfolio holdings.

Number of Shares
11,817
Previous 13,267 10.93%
Holding current value
$637,645
Previous $719,000 31.85%
% of portfolio
0.11%
Previous 0.17%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$40.25 - $52.99 $58,362 - $76,835
-1,450 Reduced 10.93%
11,817 $490,000
Q1 2024

May 03, 2024

BUY
$47.98 - $54.4 $70,386 - $79,804
1,467 Added 12.43%
13,267 $719,000
Q4 2023

Feb 13, 2024

BUY
$48.48 - $57.85 $4,848 - $5,785
100 Added 0.85%
11,800 $605,000
Q3 2020

Oct 28, 2020

SELL
$57.43 - $63.64 $38,478 - $42,638
-670 Reduced 5.42%
11,700 $705,000
Q1 2020

May 07, 2020

SELL
$46.4 - $67.43 $1,160 - $1,685
-25 Reduced 0.2%
12,370 $689,000
Q4 2019

Jan 15, 2020

BUY
$49.21 - $64.19 $23,128 - $30,169
470 Added 3.94%
12,395 $795,000
Q3 2019

Nov 04, 2019

SELL
$42.77 - $50.71 $4,277 - $5,071
-100 Reduced 0.83%
11,925 $605,000
Q2 2019

Jul 24, 2019

SELL
$44.62 - $49.34 $57,827 - $63,944
-1,296 Reduced 9.73%
12,025 $545,000
Q1 2019

Apr 29, 2019

SELL
$45.12 - $53.8 $10,106 - $12,051
-224 Reduced 1.65%
13,321 $636,000
Q3 2018

Oct 15, 2018

SELL
$55.19 - $62.25 $55,190 - $62,250
-1,000 Reduced 6.88%
13,545 $840,000
Q2 2018

Jul 30, 2018

SELL
$50.53 - $62.98 $2,526 - $3,149
-50 Reduced 0.34%
14,545 $805,000
Q1 2018

Apr 24, 2018

SELL
$59.92 - $68.98 $10,486 - $12,071
-175 Reduced 1.18%
14,595 $924,000
Q4 2017

Feb 02, 2018

SELL
$59.94 - $65.35 $447,751 - $488,164
-7,470 Reduced 33.59%
14,770 $905,000
Q3 2017

Oct 26, 2017

BUY
$55.23 - $63.74 $1.23 Million - $1.42 Million
22,240
22,240 $1.42 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $115B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Broderick Brian C Portfolio

Follow Broderick Brian C and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Broderick Brian C, based on Form 13F filings with the SEC.

News

Stay updated on Broderick Brian C with notifications on news.